Mesoblast Limited American Depositary Shares (MESO)

About MESO

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graf…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

108

Website

www.mesoblast.com/

Fundamentals

1-day range

$17.33$18.08

Market cap

$2.02B

P/E (trailing)

—

P/E (forward)

44.72

EPS (trailing)

$-0.07

Dividend yield

—

Beta

1.06

Avg. volume

226.1K

Forecasts

2 analyst ratings

Mesoblast Limited American Depositary Shares Competitors

Chosen by industry and closest market cap.

• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $2.02BP/E —
  $1.88$3.31
• RXRX

  Recursion Pharmaceuticals Inc. Class A Common Stock

  $3.33

  ▼ 3.20%
  Market cap $1.69BP/E —
  $2.77$7.18
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.44BP/E —
  $23$55.42
• VIR

  Vir Biotechnology Inc. Common Stock

  $10.83

  ▼ 4.24%
  Market cap $1.48BP/E —
• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.33BP/E —
  $4.6$25.77
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.28BP/E —
  $6.5$49.95
• NVAX

  Novavax Inc. Common Stock

  $9.27

  ▲ 2.43%
  Market cap $1.27BP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
  benzinga · 8/27/2026
• Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
  Benzinga · 8/27/2026
• Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
  Benzinga · 8/27/2026
• Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
  SeekingAlpha · 8/27/2026
• Full Transcript: Mesoblast FY 2026 Earnings Call
  Benzinga · 8/26/2026
• Flowers Foods Posts Downbeat Q2 Results, Joins OSI Systems, Aveanna Healthcare And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
  Benzinga · 8/21/2026
• Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
  Benzinga · 8/17/2026
• H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
  Benzinga · 8/17/2026
• Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
  Benzinga · 8/14/2026

• Gregory George · April 10, 2026 · Buy

  2.32M @ $1.48
• Gregory George · April 9, 2026 · Buy

  10.0K @ $14.4
• Gregory George · April 9, 2026 · Buy

  5.0K @ $14.3
• Gregory George · April 9, 2026 · Buy

  5.2K @ $14.25
• Gregory George · April 9, 2026 · Buy

  20.0K @ $14.3
• Gregory George · April 9, 2026 · Buy

  4.8K @ $14.4
• Gregory George · April 9, 2026 · Buy

  500.0K @ $14.39
• Gregory George · April 9, 2026 · Buy

  105.0K @ $1.46
• Gregory George · April 9, 2026 · Buy

  886.9K @ $1.43
• Gregory George · April 4, 2026 · Buy

  4.00M @ $1.42

Institutional Ownership

March 31, 2026

Total shares held

4.82M

Total value held

$73.50M

Institutional holders

67